BCL2 and Miyoshi myopathy: Notably, in the context of MM, in contrast to the BCL2 inhibitor venetoclax [79], S63845 showed significant activity not only in MM cell lines carrying the t(11;14) translocation but also in those carrying genetic lesions associated with poor prognosis, including t(4;14) and TP53 mutations, suggesting that MCL1 inhibitors may be effective in cases of MM refractory to standard chemotherapy [130].